Beranda › Leukemia › Massachusetts
Uji klinis Leukemia di Massachusetts
28 studi untuk Leukemia mencari peserta di lokasi di Massachusetts.
Kota di Massachusetts
Teks studi resmi (Bahasa Inggris)
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT04996875Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
- Dana-Farber Cancer Institute, Boston
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06907797Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Boston
Menerima pesertaFase 3
Usia 18 hingga 18 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07509151Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
- Massachusetts General Hospital, Boston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07249346CIML NK Cells With Venetoclax for AML
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT06152809Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Menerima pesertaFase 1
Usia 18 hingga 90 · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT07439211Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Beth Israel Deaconess Medical Center, Boston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT06001788Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Massachusetts, Worcester
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT07007312ALL Backbone in AYAs
- Dana Farber Cancer Institute, Boston
Menerima pesertaFase 2
Usia 18 hingga 51 · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT07227584Addressing Cancer Care Equity With Social Determinants of Health Screening and Early Intervention
- Mass General Brigham Cancer Institute, Boston
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Jul 2026 · NCT07671209Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
- Dana-Farber Cancer Institute, Boston
Menerima pesertaSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Jul 2026 · NCT06469307Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 19 hingga 110 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT02012699A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Boston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Jun 2026 · NCT05475925A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Menerima pesertaFase 1
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 17 Jun 2026 · NCT04024761Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Jun 2026 · NCT06138587A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Mei 2026 · NCT03219450Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Dana-Farber Cancer Institute, Boston
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 18 Mei 2026 · NCT01790152A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Apr 2026 · NCT04256317Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
- Massachusetts General Hospital Cancer Center, Boston
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Apr 2026 · NCT05646576Shwachman Diamond Syndrome Registry and Study
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 6 Apr 2026 · NCT06056908Revumenib in Combination With 7+3 + Midostaurin in AML
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 1
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 25 Mar 2026 · NCT06313437A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Massachusetts General Hospital, Boston
- UMass Chan Medical School, Worcester
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Mar 2026 · NCT05735184Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Feb 2026 · NCT06644183A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Feb 2026 · NCT07148180Mosunetuzumab for CLL MRD Clearance
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Des 2025 · NCT07052695SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2025 · NCT05842603HEME Home Transfusion Program
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2025 · NCT06487247Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.